13 completed, 11 recruiting, 5 unknown, 4 not yet recruiting. 12 Phase 2, 11 Phase 1, 4 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Cutaneous T Cell Lymphoma: new trials by email Literature Review of Cutaneous T Cell Lymphoma trials Research Report on Cutaneous T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 44 | 2026-02-12 | 2026-10-27 |
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) Ropeginterferon alfa-2b - Cutaneous T Cell Lymphoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 38 | 2025-08-27 | 2026-04-01 |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System BITR2101 - NHL, Cutaneous T Cell Lymphoma | Phase 1 | Not yet recruiting | Boston Immune Technologies and Therapeutics | 37 | 2025-08-01 | 2025-07-08 |
| Combating Cancer-Related Fatigue: A Personalized Supportive Care Program Exercise, Diet - Indolent Lymphomas, Lymphoma | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2025-06-03 | 2026-07-01 |
| Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Recruiting | Fondazione Italiana Linfomi - ETS | 400 | 2025-02-27 | 2025-12-02 | |
| Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash CLn Body Wash - Cutaneous T Cell Lymphoma | Enrolling by invitation | Northwestern University | 15 | 2025-01-14 | 2026-05-01 | |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study Follow-up - Mycosis Fungoides/Sezary Syndrome, Cutaneous T Cell Lymphoma | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 460 | 2024-11-01 | 2024-10-21 | |
| Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Completed | Fondazione Italiana Linfomi - ETS | 100 | 2024-06-06 | 2026-06-01 | |
| A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma molecular subtype based treatment - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma | Recruiting | Peking University First Hospital | 100 | 2024-05-09 | 2024-05-31 | |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas Pembrolizumab, Mogamulizumab - Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 23 | 2023-12-06 | 2026-05-05 |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light Hypericin, Visible Light - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Completed | Ellen Kim, MD | 10 | 2023-08-21 | 2026-02-09 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
| A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors SIM1811-03 or in combination with Sintilimab injectiont - Advanced Solid Tumor, Cutaneous T Cell Lymphoma | Phase 1 | Unknown | Jiangsu Simcere Biologics Co., Ltd | 255 | 2022-03-06 | 2023-09-21 |
| TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides Low-dose total-skin electron-beam therapy, Phototherapy - Mycosis Fungoides, Cutaneous T Cell Lymphoma | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 78 | 2022-02-01 | 2022-01-25 |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat [14C]-resminostat - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | 4SC AG | 5 | 2021-10-12 | 2022-02-18 |
| Photopheresis in Early-stage Mycosis Fungoides UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Recruiting | Columbia University | 74 | 2021-05-08 | 2026-04-27 |
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma Microdevices, Standard of care therapy, Standard of care systemic therapy - Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 20 | 2019-12-11 | 2026-07-27 |
Showing 20 of 40. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (40) · Mycosis Fungoides (16) · Sezary Syndrome (8) · Lymphoma (6) · Lymphoma, T-Cell, Peripheral (4) · Graft vs Host Disease (3) · Lymphoma, T-Cell (3) · Leukemia (2) · Lymphoproliferative Disorders (2) · Recurrence (2) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Colonic Neoplasms (1) · Eczema (1) · Hematologic Neoplasms (1)
Hemic and Lymphatic Diseases (40) · Lymphoma, Non-Hodgkin (40) · Neoplasms by Histologic Type (40) · Immune System Diseases (39) · Immunoproliferative Disorders (39) · Lymphatic Diseases (39) · Neoplasms (39) · Lymphoproliferative Disorders (38) · Lymphoma, T-Cell (37) · Lymphoma (34) · Hematologic Diseases (5) · Leukemia, Lymphoid (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Leukemia, T-Cell (3)
Doxorubicin (2) · Methoxsalen (2) · Radiotherapy (2) · hypericin (2) · mogamulizumab (2) · pembrolizumab (2) · Bendamustine Hydrochloride (1) · Biopsy (1) · Blood Specimen Collection (1) · Brentuximab Vedotin (1) · Capecitabine (1) · Cyclophosphamide (1) · Diet (1) · Dimethyl Fumarate (1) · Everolimus (1)
Assistance Publique - Hôpitaux de Paris (3) · Northwestern University (3) · Fondazione Italiana Linfomi - ETS (2) · UNC Lineberger Comprehensive Cancer Center (2) · University of Michigan Rogel Cancer Center (2) · 4SC AG (1) · Abramson Cancer Center at Penn Medicine (1) · Boston Immune Technologies and Therapeutics (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Dartmouth-Hitchcock Medical Center (1) · Ellen Kim, MD (1) · Falo, Louis, MD (1) · Florida Academic Dermatology Centers (1) · Galderma R&D (1)
United States (25) · France (4) · China (3) · Germany (3) · Italy (3) · United Kingdom (2) · Australia (1) · Austria (1) · Netherlands (1) · South Korea (1) · Spain (1) · Switzerland (1)
Pietro Quaglino, MD (2) · Alain H Rook, M.D. (1) · Alan Zhou (1) · Alan Zhou, MD (1) · Cecilia Larocca, MD (1) · Christopher Jensen, MD MSCR (1) · Frederick Lansigan, MD (1) · James Gulley, M.D. (1) · Jonathan Brammer, MD (1) · Kathryn Gazarik (1) · Larisa Geskin, MD (1)
PMID 19826128, PMID 21355097, PMID 21575927, PMID 25691106, PMID 25891346, PMID 26228486, PMID 28264616, PMID 32632956, PMID 33072126, PMID 34758074, PMID 35276694, PMID 37217183, PMID 37585188, PMID 37589506, PMID 38758815, PMID 39617826, PMID 39821757
2017 (1), R01CA247497 (1)